WO1997007819B1 - Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter - Google Patents
Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiterInfo
- Publication number
- WO1997007819B1 WO1997007819B1 PCT/EP1996/003733 EP9603733W WO9707819B1 WO 1997007819 B1 WO1997007819 B1 WO 1997007819B1 EP 9603733 W EP9603733 W EP 9603733W WO 9707819 B1 WO9707819 B1 WO 9707819B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- antigen
- receptor
- pharmaceutical composition
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract 18
- 108091007433 antigens Proteins 0.000 title claims abstract 18
- 102000036639 antigens Human genes 0.000 title claims abstract 18
- 239000003814 drug Substances 0.000 title claims abstract 7
- 238000009169 immunotherapy Methods 0.000 title claims 6
- 239000000203 mixture Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000012636 effector Substances 0.000 claims 6
- -1 CD45R Proteins 0.000 claims 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 102100022749 Aminopeptidase N Human genes 0.000 claims 4
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 108010029697 CD40 Ligand Proteins 0.000 claims 3
- 102100032937 CD40 ligand Human genes 0.000 claims 3
- 210000003038 endothelium Anatomy 0.000 claims 3
- 210000000981 epithelium Anatomy 0.000 claims 3
- 231100000167 toxic agent Toxicity 0.000 claims 3
- 239000003440 toxic substance Substances 0.000 claims 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 claims 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 2
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims 2
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 claims 2
- 210000001821 langerhans cell Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 231100000617 superantigen Toxicity 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Abstract
L'invention concerne des médicaments contenant des anticorps présentant au moins une spécificité, qui identifient l'antigène du MCHII d'un patient à traiter. L'invention concerne en outre des anticorps présentant deux spécificités ou plus, qui identifient l'antigène MCHII d'un patient, ainsi que des compositions diagnostiques contenant lesdits anticorps.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT96929318T ATE208630T1 (de) | 1995-08-25 | 1996-08-23 | Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen |
| DE59608213T DE59608213D1 (de) | 1995-08-25 | 1996-08-23 | Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen |
| US09/029,369 US6294167B1 (en) | 1995-08-25 | 1996-08-23 | Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated |
| EP96929318A EP0845998B1 (fr) | 1995-08-25 | 1996-08-23 | Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter |
| DK96929318T DK0845998T3 (da) | 1995-08-25 | 1996-08-23 | Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19531346.1 | 1995-08-25 | ||
| DE19531346A DE19531346A1 (de) | 1995-08-25 | 1995-08-25 | Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997007819A1 WO1997007819A1 (fr) | 1997-03-06 |
| WO1997007819B1 true WO1997007819B1 (fr) | 1997-05-15 |
Family
ID=7770409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/003733 WO1997007819A1 (fr) | 1995-08-25 | 1996-08-23 | Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6294167B1 (fr) |
| EP (1) | EP0845998B1 (fr) |
| AT (1) | ATE208630T1 (fr) |
| DE (2) | DE19531346A1 (fr) |
| DK (1) | DK0845998T3 (fr) |
| ES (1) | ES2164914T3 (fr) |
| PT (1) | PT845998E (fr) |
| WO (1) | WO1997007819A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6368596B1 (en) * | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| DE19937264A1 (de) * | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶-Antikörper-Konstrukte |
| CN1423660A (zh) * | 1999-11-18 | 2003-06-11 | 牛津生物医学（英国）有限公司 | 抗体 |
| AU2002340168A1 (en) * | 2001-10-11 | 2003-06-17 | Protein Design Labs Inc. | Treatment of prostate cancer by inhibitors of ncam2 |
| DE10261223A1 (de) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| EP1874821B1 (fr) | 2005-04-26 | 2013-04-17 | Trion Pharma Gmbh | Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer |
| GB0509318D0 (en) * | 2005-05-06 | 2005-06-15 | Chiron Srl | TCR-independent activation of T cells |
| GB0512225D0 (en) * | 2005-06-16 | 2005-07-27 | Univ Sheffield | Immunoglobulin molecules |
| EP1820513A1 (fr) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques |
| US7862813B2 (en) | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
| GB0803076D0 (en) * | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
| EP2241576A1 (fr) | 2009-04-17 | 2010-10-20 | Trion Pharma Gmbh | Utilisation des anticorps bispécifiques trifonctionnels pour le traitement des tumeurs associées aux cellules souches de cancer CD133+/EpCAM+ |
| CA2940579A1 (fr) * | 2014-03-13 | 2015-09-17 | Universitaet Basel | Ligands glucidiques qui se lient aux anticorps igm contre la glycoproteine associee a la myeline |
| WO2018099539A1 (fr) | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations |
| MX2019009468A (es) | 2017-02-08 | 2020-01-20 | Dragonfly Therapeutics Inc | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. |
| DK3582806T5 (da) | 2017-02-20 | 2024-09-02 | Dragonfly Therapeutics Inc | Proteiner, der binder her2, nkg2d og cd16 |
| BR112020016190A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpos direcionando o receptor nkg2d |
| SG11202007945UA (en) | 2018-02-20 | 2020-09-29 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| IL297922A (en) | 2020-05-06 | 2023-01-01 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and clec12a |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068790B1 (fr) * | 1981-06-25 | 1986-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Méthode immunothérapeutique allèle spécifique et forme de dosage |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
-
1995
- 1995-08-25 DE DE19531346A patent/DE19531346A1/de not_active Ceased
-
1996
- 1996-08-23 WO PCT/EP1996/003733 patent/WO1997007819A1/fr active IP Right Grant
- 1996-08-23 ES ES96929318T patent/ES2164914T3/es not_active Expired - Lifetime
- 1996-08-23 DE DE59608213T patent/DE59608213D1/de not_active Expired - Lifetime
- 1996-08-23 EP EP96929318A patent/EP0845998B1/fr not_active Expired - Lifetime
- 1996-08-23 PT PT96929318T patent/PT845998E/pt unknown
- 1996-08-23 US US09/029,369 patent/US6294167B1/en not_active Expired - Lifetime
- 1996-08-23 DK DK96929318T patent/DK0845998T3/da active
- 1996-08-23 AT AT96929318T patent/ATE208630T1/de active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997007819B1 (fr) | Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter | |
| Reinherz et al. | Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes | |
| Ciccone et al. | Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells | |
| Weiss et al. | Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line. | |
| Bonnefoy et al. | The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens. | |
| EP0403156B1 (fr) | Anticorps monoclonaux améliorés contre le récepteur alpha/bêta des cellules T humaines, leur production et leur utilisation | |
| KR100426113B1 (ko) | 티(t)-세포항원,및티(t)-세포매개증상의진단및치료에있어서의이의용도 | |
| Junghans et al. | Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders | |
| FI117900B (fi) | Menetelmä solun valmistamiseksi, joka ilmentää soluvälitteisen immuuniteetin uudelleensuuntaavia reseptorikimeeroja, ja niitä koodaava DNA ja vektori | |
| Schiller et al. | CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells | |
| US6294167B1 (en) | Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated | |
| Spertini et al. | Induction of human T cell proliferation by a monoclonal antibody to CD5. | |
| Pauza et al. | Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains. | |
| Todd III et al. | A monoclonal antibody that blocks class II histocompatibility-related immune interactions | |
| FI75598C (fi) | Foerfarande foer framstaellning av en monoklonal antikropp mot en maensklig tymocytantigen medelst en ny hybridcellinje. | |
| US20050221438A1 (en) | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same | |
| Dang et al. | FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation | |
| Heinrich et al. | Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. | |
| Alvarez-Vallina et al. | Delimitation of the proliferative stages in the human thymus indicates that cell expansion occurs before the expression of CD3 (T cell receptor). | |
| EP0241811A2 (fr) | Anticorps monoclonal contre le récepteur de l'interleukine-2 humaine | |
| Chayen et al. | Preparation and properties of a cytotoxic monoclonal rat anti-mouse Thy-1 antibody | |
| US6156882A (en) | Antibody 4G8B4B12 | |
| Lobo et al. | Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells. | |
| WO1997008205B1 (fr) | Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo | |
| US7279291B2 (en) | Polypeptides having a triggering NK activity and biological applications |